Ovid Therapeutics Inc. (OVID) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 0.25
30Y Low0.2·High0.2
P/FCF
N/A
—
5yr avg: 1.84
30Y Low1.8·High1.8
P/B Ratio
↓
1.57
+17% vs avg
5yr avg: 1.34
30Y Low0.9·High3.1
ROE
↓
-17.5%
↑-269% vs avg
5yr avg: -4.7%
30Y Low-143%·High110%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
OVID Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Ovid Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $362M | $120M | $66M | $227M | $131M | $218M | $135M | $163M | $60M | $191M | — |
| Enterprise Value | $350M | $108M | $55M | $216M | $103M | $31M | $63M | $121M | $23M | $104M | — |
| P/E Ratio → | -11.58 | — | — | — | — | 1.82 | — | — | — | — | — |
| P/S Ratio | 49.91 | 16.57 | 116.97 | 579.77 | 87.17 | 1.05 | 10.70 | — | — | — | — |
| P/B Ratio | 1.57 | 0.92 | 0.97 | 2.59 | 0.99 | 1.22 | 3.09 | 2.32 | 1.54 | 2.29 | — |
| P/FCF | — | — | — | — | — | 1.84 | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 1.84 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
OVID EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 14.96 | 96.57 | 551.61 | 68.31 | 0.15 | 4.99 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | 0.25 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | 0.25 | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 0.26 | — | — | — | — | — |
OVID Profitability
Margins and return-on-capital ratios measuring operating efficiency
Ovid Therapeutics Inc. earns an operating margin of -585.2%. Operating margins have expanded from -15122.7% to -585.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -17.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.9% | 95.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — |
| Operating Margin | -585.2% | -585.2% | -10933.7% | -15122.7% | -3696.4% | 59.6% | -645.4% | — | — | — | — |
| Net Profit Margin | -240.1% | -240.1% | -4670.1% | -13351.8% | -3604.7% | 58.9% | -642.3% | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -17.5% | -17.5% | -33.9% | -47.6% | -34.7% | 110.0% | -142.6% | -111.1% | -85.0% | -97.7% | -38.2% |
| ROA | -14.3% | -14.3% | -22.4% | -35.0% | -31.0% | 90.8% | -103.4% | -94.1% | -75.8% | -91.0% | -36.3% |
| ROIC | -36.2% | -36.2% | -69.6% | -49.2% | -86.9% | — | — | -302.6% | — | — | — |
| ROCE | -37.8% | -37.8% | -57.8% | -42.2% | -33.9% | 106.3% | -131.2% | -112.6% | -86.6% | -98.0% | -38.4% |
OVID Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $13M exceeds total debt of $1M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.22 | 0.18 | 0.13 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -0.17 | -0.13 | -0.21 | -1.04 | -1.65 | -0.60 | -0.94 | -1.04 | -1.05 |
| Net Debt / EBITDA | — | — | — | — | — | -1.51 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -1.59 | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($13M) exceeds total debt ($1M)
OVID Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Ovid Therapeutics Inc.'s current ratio of 10.91x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 9.55x to 10.91x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.91 | 10.91 | 5.32 | 9.55 | 18.79 | 12.87 | 3.39 | 7.58 | 5.01 | 14.71 | 14.04 |
| Quick Ratio | 10.91 | 10.91 | 5.32 | 9.55 | 18.79 | 12.87 | 3.39 | 7.58 | 5.01 | 14.71 | 13.97 |
| Cash Ratio | 8.40 | 8.40 | 5.04 | 9.22 | 18.45 | 12.69 | 3.26 | 7.29 | 4.69 | 14.47 | 13.91 |
| Asset Turnover | — | 0.05 | 0.01 | 0.00 | 0.01 | 1.07 | 0.17 | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | 4.10 | — | — | — | — |
OVID Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Ovid Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 54.8% | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 54.2% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $74M | $71M | $71M | $70M | $68M | $58M | $39M | $25M | $19M | $20M |
Peer Comparison
Compare OVID with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 OVIDYou | $362M | -11.6 | — | — | 95.9% | -585.2% | -17.5% | -36.2% | — |
 ACAD | $4B | 9.4 | 25.6 | 35.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 LGND | $5B | -1057.0 | 356.7 | 59.1 | 93.4% | -13.5% | -0.5% | -2.3% | 0.6 |
 RARE | $3B | -4.4 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 PTCT | $6B | 8.6 | 5.6 | 7.9 | 95.9% | 49.5% | — | — | 0.5 |
 FOLD | $4B | -80.5 | 140.6 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
 KRYS | $9B | 42.2 | 47.8 | 45.1 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 ARVN | $656M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 MDGL | $12B | -42.0 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 ZYME | $2B | -25.6 | 0.3 | — | 89.8% | -87.3% | -26.7% | -25.9% | 0.0 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
See OVID's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OVID Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OVID vs ACAD
Side-by-side business, growth, and profitability comparison vs ACADIA Pharmaceuticals Inc..
Start ComparisonOVID — Frequently Asked Questions
Quick answers to the most common questions about buying OVID stock.
What is Ovid Therapeutics Inc.'s P/E ratio?
Ovid Therapeutics Inc.'s current P/E ratio is -11.6x. The historical average is 1.8x.
What is Ovid Therapeutics Inc.'s ROE?
Ovid Therapeutics Inc.'s return on equity (ROE) is -17.5%. The historical average is -45.3%.
Is OVID stock overvalued?
Based on historical data, Ovid Therapeutics Inc. is trading at a P/E of -11.6x. Compare with industry peers and growth rates for a complete picture.
What are Ovid Therapeutics Inc.'s profit margins?
Ovid Therapeutics Inc. has 95.9% gross margin and -585.2% operating margin.